APBCS Speakers

Aaron is a Senior Resident Physician at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney. His current research focus is in early phase clinical trials and lung cancer translational research. He also has a keen interest in the design and conduct of early and late phase clinical trials. As an early career researcher, he has received numerous awards and achievements including an International Association for the Study of Lung Cancer (IASLC) Fellowship 2018-2020, ASCO 2018, ESMO Asia 2019 and WCLC 2020 Merit Awards.

Dr Andrea Wong completed her undergraduate medical degree at the University of Glasgow, and obtained her postgraduate qualifications from the Royal College of Physicians, United Kingdom as well as the National University of Singapore. She specializes in breast and brain cancers and actively contributes to cancer research through her role as an investigator in several clinical trials conducted at the National University Cancer Institute, Singapore (NCIS). She is currently performing translational research work related to the development of novel targeted therapies for the treatment of advanced cancer in her capacity as an Adjunct Research Fellow at the Cancer Science Institute, Singapore. She has received multiple research grants for her work, including the Singapore National Medical Research Council Transition Award in 2018. In addition, she has authored several publications in peer-reviewed oncology and pharmacogenetics journals, and is a member of the Singapore Society of Oncology.

Dr Brendan Pang obtained the FRCPath (UK) and qualified as a histopathologist. He then trained in the Diagnostic Molecular Oncology Centre (DMOC), a College of American Pathologists (CAP) accredited molecular diagnostic laboratory under the mentorship of Professor Manuel Salto-Tellez. He furthered his training in molecular pathology as a visiting scholar at the University of Pittsburgh Medical Centre’s (UPMC) Molecular Anatomic Pathology (MAP) laboratory, Presbyterian Hospital, under Dr Marina Nikiforova, chair-elect of the solid tumours sub-division of the Association of Molecular pathology (AMP) and returned to Singapore as the Director of DMOC. He was appointed as an honorary pathology fellow at the Cancer Science Institute (CSI) in 2012 and has had research collaborations with the Genome Institute of Singapore (GIS) and other PIs from the Yong Loo Lin School of Medicine. His research interests lie in the development of novel biomarker assays using molecular platforms.

Dr Yip is currently a consultant breast surgeon in Ramsay Sime Darby Health Care in Malaysia, and holds an appointment as Clinical Professor in the Faculty of Medicine, University Tunku Abdul Rahman, and Kuala Lumpur. She is also the lead clinician for the breast cancer research program in the Cancer Research Malaysia, which is a charity-based cancer research organization. She has been appointed an expert in cancer control by the World Health Organization and the International Atomic Energy Agency (IAEA), and has been on expert panels in international organizations such as the International Cancer Control Conference, and the Breast Health Global Initiative.

Don Dizon is the Director of the Pelvic Malignancies Program at Lifespan Cancer Institute, Head of Community Outreach and Engagement at The Cancer Center at Brown University, and Director of Medical Oncology at Rhode Island Hospital. Among his editorial roles, he is section editor in Gynecologic Oncology at UpToDate, Associate Editor at The Oncologist and serves on multiple editorial boards. He maintains online columns for Medscape, ASCO and for the journal, The Oncologist and is the chair of the Digital Engagement Committee for SWOG, a member of the National Clinical Trials Network (NCTN). He is a fellow of the American College of Physicians (FACP) and the American Society of Clinical Oncology (FASCO). In 2017, he collaborated with colleagues across the United States and founded the Collaboration for Outcomes using Social Media in Oncology.

Dr Lim Wei Tching Faye Lynnette works at National Cancer Centre Singapore in the Division of Radiation Oncology as a Consultant BMedSci (Nottingham), MBBS (Nottingham), MRCP (UK), FRCR (Clinical Oncology)(UK). Her area of specialty is Radiation Oncology and sub-specialties are Breast, Hepato-Pancreato-Biliary, Upper Gastrointestinal, and Colorectal.

Hope S. Rugo, MD, FASCO, is professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she is also the director of Breast Oncology and Clinical Trials Education. Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California San Francisco in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr Jack Chan is a Consultant Medical Oncologist. His subspecialty interests are gynaecological cancers and breast cancer. His research interests include early and late phase clinical trials and translational work in these cancers. He is the Principal Investigator of investigator-initiated and industry-sponsored trials at National Cancer Centre Singapore. Dr Chan is also active in teaching Senior Residents, medical officers, medical and nursing students; as well as in professional societies such as Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore. He has received accolades for his education and clinical work, including Residency in SingHealth Excels Outstanding Faculty Award 2020 and Singapore Health Quality Service Awards (Silver 2019, Gold 2020).

Janice Tsang is a Specialist in Medical Oncology and the Honorary Clinical Assistant Professor at the Li Ka Shing Faculty of Medicine, HKU, and Founding Convenor of HKBOG, Hong Kong. Dr Tsang’s research interests lie mainly in breast oncology, geriatric oncology, translational research and psycho-oncology. Being the first female academic medical oncologist at The University of Hong Kong (HKU), she was awarded the 2014 Hong Kong Ten Outstanding Young Persons Award, and the 2012 Hong Kong City Lady Award (Professional & Academic Category) as the only medical professional receiving this award for the year. She was also the winner of the Psychosocial Oncology Young Investigator Award at the 16th Hong Kong International Cancer Congress & 6th Annual Meeting of Centre for Cancer Research in 2009, and was bestowed the Faculty Teaching Medal in 2012, and the Outstanding Teaching Award (Team Award) for Medical Humanities in 2013 in recognition of her being one of the pioneers in incorporating medical humanities in the formal medical curriculum. She has conducted over 80 clinical trials, including local, regional and international multicenter clinical trials. She has been serving as Chairperson for the Data Monitoring Committee, Steering Committee members for major multi-centered clinical trials, as well as various international and regional advisory boards. She is a key opinion leader in breast oncology both locally and regionally. She is also the Founding Convenor of the HKBOG, which is now a member of the ‘Breast International Group’, being the 3rd Asian member after Japan and Taiwan. She is also appointed as Chair of the CTRG Audit Committee for the National Cancer Institute in 2017, and a member of the International Society of Geriatric Oncology (SIOG), serving as co-track chair for translational research in SIOG. She is also the Co-Chair of the Organizing Committee of the 8th Global Chinese Breast Cancer Organizations Alliance Conference 2021. Dr Tsang is currently member of the Specialty Board of Medical Oncology and used to be the Programme Director for Medical Oncology in the Hong Kong Island at the Hong Kong College of Physicians; a member of the Coordinating Committee (CoC) for Medical Oncology at the Hospital Authority; Deputy Chairperson for the Institutional Review Board for the Hong Kong West Cluster/HKU; and Director of Cancer Centre at Queen Mary Hospital, Hong Kong. She has various appointments in different professional bodies, such as Honorary Advisor for various cancer self-help groups, including the Hong Kong Christian Cancer Care Association and the Hong Kong Cancer Fund. Furthermore, she serves as member of the Social Welfare Advisory Committee and the Rehabilitation Advisory Committee in Hong Kong. She also serves as Deputy Chairman for the Women for Oncology Committee at the European Society of Medical Oncology (ESMO) for the term of 2020–2021, and as Founding Convenor of the Hong Kong Women for Oncology (HKW4O).

Dr Javier Cortes is head of breast cancer and gynecological cancers at Hospital Universitario Ramón y Cajal in Madrid, Spain, as well as Clinical Investigator in the breast cancer research program at Vall d’Hebron Institute of Oncology in Barcelona, Spain. He is one of the European leaders in the field of HER2+ breast cancer, and has led fundamental trials that resulted in the approval of pertuzumab, eribulin and everolimus for metastatic breast cancer. He continues to actively participate in national and international clinical investigations to develop molecularly targeted therapies, such as CDK 4/6 inhibitors, and immunotherapies. Dr Cortés is on the Scientific Committee of ESMO and is an active member of ASCO and the Spanish Society of Medical Oncology.

Dr Joline Lim is Consultant at the Department of Haematology-Oncology at the National University Cancer Institute, Singapore – NCIS (part of NUHS). Joline’s study on “Combination and triplet therapy for breast cancer patients” was an early phase clinical trial investigating a novel combination of targeted cancer treatments to understand its effect on patients with advanced refractory cancers. The study successfully showed that this combination had the potential to improve patient outcomes, especially in breast cancer patients for which hormonal therapy is no longer effective.

Dr Karmen Wong is a medical oncologist with more than 30 years of clinical practice. She received her oncology training at the National University Hospital (NUH), National Cancer Centre, Singapore (NCC) and University of California, San Francisco (UCSF), who have a reputation for health sciences research and patient care under the HMDP scholarship. She helped establish the first multi-disciplinary breast cancer treatment in Singapore 20 years ago in NCC, which created a platform for treatment in other cancer types with doctors of different disciplines. Dr Wong also initiated the bone marrow transplant programme in solid tumour in Singapore General Hospital (SGH) in 1997. She also won an award for her oral presentation at the 9th Annual Scientific Meeting in SGH in 1988. She is also currently running a strong cancer support network in her practice. In addition, she is also a co-investigator in various clinical trials on new cancer treatments. These include the CompLEEment-1 trial study that were presented in ASCO 2019 (American Society of Medical Oncology) and ESMO 2018 (European Society for Medical Oncology) meetings. Dr Wong presented the 1st Asian study in attitudes towards breast cancer treatment among Asian patients in the Annual Meeting of the American Society of Clinical Oncology in 1999. She has also written numerous peer review articles and published chapters in textbooks. She also gives lectures in the ASEAN regions on cancer treatment updates. Dr Karmen Wong accepts referrals for all cancer types, with a special clinical interest in breast, gastrointestinal and gynaecological cancers.

Professor Kim Tae Hyun is currently the Chief Professor in the Department of General Surgery & Director at Breast Center in Inje University, Busan Paik Hospital South Korea. He is also the Director of International Relations Committee, Korean Breast Cancer Society, Director of Public Relations Committee, Korean Association of Thyroid and Endocrine Surgeons, the President, Busan-Ulsan-Kyeongnam Breast Cancer Society and Vice President of the Korean Breast Cancer Society

Dr. Komal Jhaveri is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. At MSK, she conducts translational research in collaboration with my laboratory colleagues to shepherd our findings from the lab to the clinic. Through her research, she aims to accelerate the development of new treatments and improve outcomes for people with breast cancer.

Assoc. Prof. Lalit Krishna is a Senior Consultant in the Division of Supportive and Palliative Care, National Cancer Centre Singapore. He holds a master’s in Medical Ethics, a master’s in Medical Education and a PhD in Medical Ethics. Assoc Prof Lalit also holds appointments of Associate Professor at Duke-NUS Medical School Singapore, and Clinical Senior Lecturer at Yong Loo Lin School of Medicine, National University of Singapore. He has recently taken up the post of Director of Practice Course 2 at Duke-NUS and Director of Phase IV and V at the Centre of Biomedical Ethics at NUS. He is the chairman of the Clinical Ethics Committee and the Internal Audit Committee at NCCS.

Dr Lee obtained her medical degrees from the National University of Singapore and the Royal College of Physicians, United Kingdom, and completed a fellowship in cancer genetics at Johns Hopkins School of Medicine, United States. She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specializes in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumors and haematological malignancies at the National University Cancer Institute.

Dr Lim Siew Eng is Senior Consultant and Associate Director (Clinical) at the Department of Haematology- Oncology, National University Cancer Institute, Singapore (NCIS). Dr Lim previously held the appointments of Postgraduate Training Director and has won multiple service awards for her work with hospital and patients. She obtained her basic medical qualifications from the Royal College of Surgeons, Ireland and received further Internal Medicine training at Thomas Jefferson University Hospital, Philadelphia. She was appointed Clinical Fellow at Harvard Medical School, USA and completed training in Medical Oncology at Beth Israel Hospital, Boston. Dr Lim specialises in Breast Cancer and Gynaecologic Cancer. She has also worked with committees of Singapore Society of Oncology and Singapore Cancer Society to advance cancer programs and awareness and she serves as chair of the Chapter of Medical Oncology, College of Physicians, Singapore. Dr Lim has authored or co-authored publications in peer-reviewed local and international journals.

Dr Lim Sue Zann is a Consultant in the Department of General Surgery, Singapore General Hospital. She graduated with Honours from the Faculty of Medicine, University of Malaya in 2008. She completed her specialty training in Singapore General Hospital and achieved specialist accreditation in 2017. At the same time, she became a Fellow of the Royal College of Surgeons of Edinburgh. Currently she is undergoing a fellowship in Advanced Breast Surgery within the SingHealth Duke-NUS Breast Centre and Department of Reconstructive and Aesthetic Surgery, Singapore General Hospital. She will further hone her skills in oncological and reconstructive breast surgery during this time. Dr Lim Sue Zann is actively involved in medical education. She is a Clinical Lecturer at NUS Yong Loo Lin School of Medicine and Physician Faculty Member at SingHealth General Surgery Residency Program. She received the Dean’s Award for Teaching Excellence from NUS Yong Loo Lin School of Medicine in 2013. Her research interests are in breast sarcoma and phyllodes tumours. She was awarded the Singapore General Hospital Research Grant in 2016 to further her work in these tumours. She has presented at surgical conferences and published papers on breast surgery.

Yen-Shen Lu is currently Clinical Professor of Medicine at the National Taiwan University College of Medicine, as well as Division Chief of Medical Oncology at Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Dr Lu graduated from the Chinese Medical College, Taichung, in 1992 and obtained his PhD from the National Taiwan University, Taipei, Taiwan, in 2006. During 2005-2006. Dr. Lu has extensive experience as a translational researcher, clinical trial initiator, protocol writer, clinical trial steering committee member/chair, and as a principal investigator or co-principal investigator for more than 80 clinical trials, with particular focus on targeted agents in metastatic breast cancer, especially ER+ disease and breast cancer with brain metastases. He was the co-chair of steering committee of MONALEESA-7 trial, and chair of steering committee of BYOND and RIGHT Choice trials. He is currently lead member of Asian Breast Cancer Cooperative Group, and member of Scientific Committee of TRIO (Translational Research in Oncology). He has received the Scholar in Training Award at the 92nd Annual Meeting of the American Association Cancer Research in 2001, Chien-Tien Hsu's Outstanding Cancer Research Award in 2019, Mistry of Science and Technology Outstanding Research Award in 2020. Additionally, Dr. Lu led a series of studies focusing on young female breast cancer, regarding to the epidemiology, biology, and genetic differences between East and Western. He is first or corresponding author of articles published in many high impact peer-reviewed international journals, including New England Journal of Medicine, Lancet Oncology, Journal of National Cancer Institute, Journal of Clinical Oncology, and Clinical Cancer Research.

Dr Mabel Wong is a Senior Consultant and Head of the Breast and Gynaecology Department, Division of Medical Oncology at National Cancer Centre Singapore. She is also a Visiting Senior Consultant at the Breast Service, KK Hospital. She obtained her undergraduate medical degree from the National University of Singapore and underwent fellowship training at The Royal Marsden, United Kingdom. Dr. Wong has been practicing in Singapore since 2001, focusing mainly on medical oncology since 2008. Her research interests include clinical trials in breast and gynaecology oncology and neo-adjuvant therapy in breast cancer.

Dr. Mastura Md Yusof's area of expertise in clinical oncology encompasses radiation therapy, medical oncology and cancer palliation as well as clinical research in breast, colorectal and gastrointestinal cancers and various cancer sites. For her outstanding work and efforts, Dr Mastura was awarded the Universiti Malaya Excellent award for 2014. Dr Mastura serves as consultant in various advisory boards and expert committee panels for cancer and cancer-related services in government such as good oncology practice and chemotherapy protocol guideline, as well as in private sectors. Dr Mastura is currently an EXCO member of the Malaysian Oncological Society and a member of the Academy of Medicine Malaysia (AM), European Society of Medical Oncology, American Society of Clinical Oncology and European Society for Therapeutic Radiology and Oncology. She has worked and shared her expertise with NGOs championing cancer awareness, early diagnosis and treatment within Malaysia and South East Asia.

Dr. Neil Iyengar is a board-certified Medical Oncologist and clinical-translational researcher at Memorial Sloan Kettering Cancer Center (MSKCC) where he specializes in the care of patients with breast cancer. He also holds joint research appointments at the Rockefeller University Center for Clinical and Translational Science and Weill Cornell Medicine in New York. Dr. Iyengar received his undergraduate and medical degrees from the University of Illinois at Chicago accelerated degree program where he graduated with the College’s highest honors (University Scholar). He completed residency training in Internal Medicine at the University of Chicago Medical Center followed by fellowship in medical oncology and hematology at MSKCC. He now holds a faculty position as an Associate Attending on the Breast Medicine Service at MSKCC. Dr. Iyengar’s research program investigates interventions to improve metabolic health as a strategy to reduce breast cancer risk and mortality. His group is testing the anti-cancer effects of structured exercise and nutritional interventions in people at high risk or diagnosed with breast cancer. Dr. Iyengar’s research is also investigating the use of drugs that treat metabolic disorders, such as diabetes and obesity, to improve the effectiveness of cancer therapies. In an effort to rapidly translate this work, Dr. Iyengar also leads the Healthy Living Program, a novel cancer care model that aims to translate research findings from lifestyle intervention trials into clinical practice during and after cancer therapy. His work has been recognized and awarded by several organizations, including research grants from the National Cancer Institute, American Cancer Society, the Breast Cancer Research Foundation, Conquer Cancer the ASCO Foundation, and others. He has published numerous original research articles and has been an invited speaker at several international conferences.

Dr Peter Ang is a consultant medical oncologist in private practice at OncoCare Cancer Centre. His undergraduate medical training is at the National University of Singapore and his postgraduate medical oncology training was in Singapore and Dana-Farber Cancer Institute in Boston, USA. His clinical practice and clinical interest is in breast cancer and cancer genetics, with publications in P53, PALB2, BRCA1, BRCA2 in local and international journals.

Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials.

Dr Samuel Ow is a Consultant Medical Oncologist in the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS). He obtained his medical degree from the Yong Loo Lin School of Medicine, National University of Singapore, where he was awarded Distinction in Medicine, the Nestle Gold Medal, and placed on the Dean’s List for his academic achievements. He received the Dean’s Award for Outstanding House Officer of his entire cohort in 2007, and obtained the Masters of Medicine (Internal Medicine) and Membership of the Royal College of Physicians (UK) on an MOHH Postgraduate Exam Scholarship in 2011. He subsequently successfully completed his specialty training in Internal Medicine and Medical Oncology at NCIS where he served as Chief Registrar, and was also selected for the inaugural Singapore Chief Residency Program. Dr Samuel Ow’s clinical and research interests are in Breast Cancer and Clinical Cancer Genetics. He received a Master of Public Heath with concentration in Epidemiology and Biostatistics from the Johns Hopkins Bloomberg School of Public Health on an Academic Medicine Development Award in 2016. During his time in Baltimore, USA, he also attended sessions at the Sidney Kimmel Comprehensive Cancer Center. He is a co-investigator in several investigator-initiated and multi-national clinical trials. His research work has been published in peer-reviewed journals as well as at the American Society of Clinical Oncology Annual Meeting. He is an alumnus of the Clinical Cancer Genetics Community of Practice Intensive Course in Cancer Risk Assessment conducted by the City of Hope Comprehensive Cancer Center, and currently runs the Cancer Genetics Clinic at NCIS. He also sits on the committee for the Breast Cancer Awareness Campaign at the institutional and national level, to help drive greater awareness for breast cancer screening and prevention in the general public. Dr Samuel Ow strongly believes in the importance of training the next generation of physicians. He is an Assistant Professor on the Clinician-Educator track at the Yong Loo Lin School of Medicine, and is currently the Associate Program Director of the Medical Oncology Senior Residency Program at NCIS. He is active in medical education at the undergraduate and postgraduate level, and has been awarded for teaching excellence. On the administrative front, Dr Samuel Ow serves as Assistant Clinical Director of the Division of Medical Oncology, and is involved in improving processes to enhance clinical care in cancer patients. He is an advocate for multidisciplinary collaboration, and notably led a team from NCIS to win the Best Practice Medal (Care Redesign Category) at the National Healthcare Innovation and Productivity Medals 2019.

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on the development of novel therapies in the treatment of breast cancer.

Dr See Hui Ti is a Senior Consultant, Medical Oncologist at Parkway Cancer Centre. Dr See was awarded the Singapore Government HMDP fellowship in 2002 after completing advanced oncology training at the National Cancer Centre. From 2003 to 2004, she furthered her training in Medical Oncology at the M.D. Anderson Cancer Center in Houston, Texas. She has recently obtained her fellowship from the college of physicians (FRCP) from Edinburgh.

Dr Shaheenah Dawood is a Consultant Medical Oncologist and Professor in Clinical Oncology in the United Arab Emirates. She was trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training, she was awarded multiple scholar training awards besides ASCO merit awards. Dr Shaheenah has served as an editorial fellow at the New England Journal of Medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles, and 12 book chapters. Having served as a reviewer for multiple journals including the Journal of Clinical Oncology she is currently leading the oncology clinical trials program at Mediclinic City Hospital, Dubai. She also serves as President of Excellence in Oncology Care (EIOC) annual congress held in Dubai and is Co-Chair of the Asia Pacific Breast Cancer Summit (APBCS), Asia Pacific Gastrointestinal Cancer Summit (APGCS) ,the international BRCA forum (iBRCAf) and Young Women Forum (YWF) from over a decade.

Dr Steven Tucker is a Consultant Medical Oncologist and Founder of Tucker Medical, a Singapore-based multi-specialty practice combining primary care and sub-specialty medicine. It is the mission of Tucker Medical to provide team-based comprehensive care and prevention to patients and their families across the continuum of health and disease. Dr Tucker trained in Internal Medicine, Haematology, Oncology, and Stem Cell Transplantation at the UCLA Centre for Health Sciences. While at UCLA, he studied molecular biology and joined the UCLA faculty as an Assistant Professor of Clinical Medicine in 1999. Dr Tucker is a Fellow of the Singapore Academy of Medicine and the American College of Physicians. He has received numerous honours, including an ASCO Merit Award, an NIH Commendation, the UCLA ‘STAR’ Program Award, and a Pew Foundation Fellowship. Dr Tucker cares for patients with all cancer types and has a particular interest in the prevention and treatment of breast and prostate cancer. Dr Tucker has extensive experience in digital and population health. He was Chief Medical Officer at CXA Group and previously held consulting and strategic roles at MetLife Asia, Lumen Lab Innovation Centre, and was the founding Global Health Advisor at Singtel. Outside of clinical practice, Dr Tucker is a professional speaker, strategist, and consultant advising start-ups, venture funds, and governments on integrating new technologies such as genomics, AI, and remote monitoring in health and medicine. He is a Senior Health Advisor at Beyond Limits AI and a faculty member at the Singapore-MIT Alliance for Research and Technology (SMART), teaching medical innovation, design thinking, and entrepreneurship.

Dr. Sung-Bae Kim is a Professor at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. He attained his MD and PhD from Kyunghee University Medical School, completed clinical training in internal medicine at Ewha Womans University and undertook a clinical fellowship at Division of Hematology-Oncology at Asan Medical Center. He studied Experimental Transplantation and Immunology at the National Cancer Institute, Maryland, USA in 2000 as a postdoctoral fellow. Dr. Kim is affiliated with many professional associations, which include the Korean Medical Association, Korean Association for Internal Medicine, Korean Cancer Association, Korean Society of Breast Cancer, American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and the European Society for Medical Oncology (ESMO).

Dr. Thomas Hofmarcher is a health economist at the Swedish Institute for Health Economics (IHE). A core focus of his work is the comparative analysis of health systems and cancer policies around the world. He has led several major international projects on cancer care, studying access to cancer drugs as well as calculating the economic costs of cancer. His work on cancer has resulted in several research articles, policy reports, and book chapters. While most of his earlier work focused on Europe, recent and current work covers also the Asia-Pacific region, and the Middle East and Africa. His research has been covered extensively in international media. He is also a regular speaker at international policy events and workshops.

Dr Tira Tan is a consultant medical oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the divisional deputy director of research as well as a primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.

Dr. Valerie Heong is a medical oncologist at Tan Tock Seng Hospital. She received her medical degree from the University of Adelaide, Australia and subsequently trained in medical oncology in Melbourne, Victoria, Australia. She obtained a PhD in molecular biology from the Department of Medical Biology, University of Melbourne, Australia and subsequently moved to Singapore. During her PhD she was awarded the Ovarian Cancer Australia Postgraduate Scholarship and the Bev Gray Ovarian Cancer PhD Scholarship. She is a clinician scientist with a special interest in cancer genetics, breast and gynaecological cancer, drug development and translational research. Her research focuses on development of novel therapeutic agents and biomarker discovery in breast and ovarian cancer.

Dr. Virginia G. Kaklamani is a professor of medicine in the division of hematology/oncology at UT Health San Antonio and is the leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center. Dr. Kaklamani completed her medical training with honors at the University of Athens and her residency in internal medicine at Newton-Wellesley Hospital in Boston. She completed her fellowship in hematology/oncology at Northwestern University. She also received a master of science degree in clinical investigation from Northwestern University. She was head of the Translational Breast Cancer Program at Northwestern University and co-director of Northwestern's cancer genetics program. Her research interests include studying high-risk families and identifying genetic mutations that are associated with an increased risk for breast, colon and prostate cancer. She has identified several genetic mutations related to obesity that increase the risk of breast cancer. Dr. Kaklamani is a clinical investigator with expertise in designing clinical trials with targeted agents.

Professor Winnie Yeo graduated from King’s College Hospital, University of London. She underwent postgraduate training in Addenbrooke’s Hospital, Cambridge, and at King’s College, Westminster and Royal Marsden Hospitals in London before returning to Hong Kong. Professor Yeo was the Chairman of the Medical Oncology Specialty of the Hong Kong College of Physicians between 2007 and 2013. She is an Honorary Consultant in the Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong and a Co-director of the Comprehensive Cancer Trials Unit of the Department of Clinical Oncology, Faculty of Medicine, the Chinese University of Hong Kong. She serves as a member and advisor in various expert panels and committees within the University, the Hong Kong Hospital Authority and various health advisory panels. She has authored and coauthored over 230 papers including leading authorships for publications in journals including Journal of the National Cancer Institute, Journal of Clinical Oncology, Hepatology, Annals of Oncology etc. Her main research interests are management of breast, liver and gastric cancer patients as well as hepatitis B virus-related complications in cancer patients.

Dr Wong Nan Soon is an oncologist practising at Gleneagles Hospital and Mount Elizabeth Hospitals, Singapore. His subspecialty interests are in breast cancer and gastrointestinal cancer. He completed his advanced specialty training in general medical oncology in 2003, and subsequently a clinical fellowship subspecializing in breast medical oncology in Sunnybrook and Women’s Health Science Centre in Canada, where he trained under world-renowned breast oncologists including Professor Kathleen Pritchard. He was promoted to the position of consultant in 2006 and subsequently rose to the position of senior consultant and chief of the breast team in the department of medical oncology at National Cancer Centre, Singapore.

Dr Yoon-Sim Yap is a Senior Consultant in the Department of Medical Oncology at National Cancer Centre Singapore, and Visiting Consultant at KK Women’s and Children’s Hospital. She obtained her undergraduate medical degree from the University of Adelaide in Australia, and is a Fellow of the Royal Australasian College of Physicians. Dr. Yap has been practicing in Singapore since 2006, focusing mainly on breast cancer. Dr. Yap also aims to promote cancer awareness in the local population through public education, and provide holistic management of cancer patients through patient support groups and programs.

Associate Professor Yoland Antill is a Medical Oncologist and Cancer Genetics specialist in Victoria with appointments at Cabrini and Peninsula Health together with and Royal Melbourne Hospital. She is a Clinician Researcher and holds an adjunct clinical position in the Faculty of Medicine, Dentistry and Health Sciences at Monash University. She has more than 25 years' experience in both medical oncology and in the diagnosis and management of hereditary cancer syndromes and has published widely in these areas. Her working and research interests are in the management of Breast and Gynaecological cancers together with Hereditary Cancer Syndromes. She the deputy chair of the Australian and New Zealand Gynaecology Oncology Group (ANZGOG) Research Advisory Board, a senior executive member of the Endometrial Cancer Research Steering Committee (EDEN) and the acting chair of the Monash Molecular Tumour Board in Gynaecology.